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Background: In previous studies in virologically suppressed patients, protease inhibitor
monotherapy has shown trends for more low-level elevations in HIV-1 RNA compared
with triple therapy, but no increase in the risk of drug resistance.
Methods: A total of 273 patients with HIV-1 RNA less than 50 copies/ml on first-line
antiretrovirals switched to darunavir/ritonavir (DRV/r) 800/100mg once daily, either as
monotherapy (n¼137) or as triple therapy with two nucleoside analogues (n¼136).
Treatment failure was defined as HIV-1 RNA levels 50 copies/ml or above, or discon-
tinuation of study treatment by week 48 (FDA Snapshot algorithm).
Results: Patients were 83% male and 88% white, with mean age 42 years. In the
primary efficacy analysis, HIV-1 RNA less than 50 copies/ml by week 48 [intention-to-
treat (ITT)] was 118 of 137 (86%) in the DRV/r monotherapy arm versus 129 of 136
(95%) in the triple therapy arm (difference¼8.7%, 95% confidence interval 15.50,
1.80). In a post-hoc analysis, for patients with nadir CD4þ cell count 200 cells/ml or
above, rates of HIV-1 RNA suppression were 91 of 96 (95%) in the DRV/r monotherapy
arm and 100 of 106 (94%) in the triple therapy arm. There was no difference in
neurocognitive function or the risk of neuropsychiatric adverse events between DRV/r
monotherapy and triple therapy. Two patients in themonotherapy armwith CD4þ nadir
less than 200 cells/ml developed viraemia in both cerebrospinal fluid (CSF) and plasma,
with one symptomatic case.
Conclusions: In this study for patients with HIV-1 RNA less than 50 copies/ml at
baseline, switching to DRV/r monotherapy showed lower efficacy versus triple therapy
at week 48 in the primary ITT switch equals failure analysis, with two cases of viraemia
in the CSF in the protease inhibitor monotherapy arm.
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Introduction
Despite the success of protease inhibitor-based treatment
[1], long-term use of combination antiretroviral therapy
may be impaired by a variety of factors, including poor
adherence, pill burden, and toxicity, and presents a high
financial cost to healthcare systems [2,3]. Protease
inhibitor monotherapy has been explored as a mainten-
ance strategy in patients virologically suppressed on
antiretrovirals to reduce the impact of these issues while
aiming to maintain HIV-1 RNA suppression. Two meta-
analyses have shown that patients switching to protease
inhibitor monotherapy have a lower chance of main-
taining HIV-1 RNA suppression [4,5]. However, in both
analyses, there was similar efficacy between protease
inhibitor monotherapy and triple therapy when reintro-
duction of the nucleoside/nucleotide reverse transcrip-
tase inhibitor (NRTI) backbone was permitted.
Furthermore, when used as monotherapy, there is a
theoretical concern that protease inhibitors may not
sufficiently penetrate into the central nervous system
(CNS) and the protease inhibitor concentration observed
may not be sufficient to suppress HIV-1 in this
compartment [6]. If this is the case, the ongoing
replication of HIV-1 in the cerebrospinal fluid (CSF)
could lead to a variety of neuropsychiatric disorders and
neurocognitive impairment [6,7]. Although evidence
generally indicates that this is not the case, the concern is a
potential barrier to a widespread protease inhibitor
monotherapy approach and has not been evaluated
systematically in most previous trials of protease inhibitor
monotherapy [6,7].
Darunavir boosted with ritonavir (DRV/r) has shown
high levels of efficacy in treatment-naive and treatment-
experienced patients when co-administered with other
antiretrovirals [8,9]. Moreover, darunavir has a high
genetic barrier to the development of resistance, a long
half-life compared with other protease inhibitors, and a
favorable toxicity profile, making it an ideal candidate for
use in monotherapy [10,11].
The efficacy of DRV/r monotherapy versus DRV/r plus
two nucleoside analogues has been evaluated in patients
suppressed on their previous regimen and without prior
failure [12,13]. In both the MONET and MONOI
studies, a trend for more low-level elevations in plasma
HIV-1 RNA in the monotherapy arm compared with the
triple therapy arm was observed. The long-term results of
both studies suggest noninferior efficacy of DRV/r
monotherapy compared with triple therapy provided that
NRTI backbone can be re-introduced as necessary [14–
16]. In the ongoing 5-year PIVOT study, protease
inhibitor monotherapy was noninferior to triple therapy
in preserving future treatment options, however was
associated with a higher occurrence of viral rebound [17].
In these trials, the risk of drug resistance was minimal, and
both regimens resulted in a similar number of adverse
events. Together, these results suggest that DRV/r
monotherapy could represent a durable and efficacious
option when used as a tailored treatment option for
patients fully suppressed on triple therapy.
Monotherapy with a boosted protease inhibitor is
currently not standard-of-care, but has been included
in some treatment guidelines, such as the European AIDS
Clinical Society (EACS) guidelines, as a treatment option
in suppressed patients without prior failure to protease
inhibitors [18]. This recommendation is currently
omitted from other guidelines [19–21].
The aim of the PROTEA trial was to assess the
noninferiority of monotherapy therapy with DRV/r
versus DRV/r triple therapy, and to evaluate the safety and
tolerability of the regimen. Neurocognitive function was
assessed throughout the study to determine whether
protease inhibitor monotherapy confers a higher risk of
neurocognitive impairment. Furthermore, lumbar punc-
tures were performed in a subset of participants to assess
viral replication in the CNS. Such comprehensive CNS
evaluations were not performed in the previous studies of
DRV/r monotherapy.
Methods
PROTEAwas a 96-week, randomized, open-label phase
3b study, with study centers in 13 European countries
and Israel. The trial recruited patients who had HIV-1
RNA suppression below 50 copies/ml on their first-line
antiretroviral regimen for the 48weeks prior to screening.
Key exclusion criteria included patients with a CD4þ
count 100 cells/ml or less at the start of antiretroviral
therapy (nadir) and 200 cells/ml or less at screening,
history of virological failure or prior protease inhibitor
mutations.
During the study, the protocol was amended to allow
intensification with nucleoside analogues for any patient
in the monotherapy arm who had entered the trial with a
CD4þ nadir below 100 cells/ml. This amendment was
introduced because patients with CD4þ nadir below
100 cells/ml were protocol violators and should not be
receiving protease inhibitor monotherapy.
Subsequent to screening, patients entered a 4-week run-
in period (baseline 1) in which all patients received DRV/
r 800/100mg once daily with their current two NRTIs.
Patients were then randomized (baseline 2) 1 : 1 to receive
either DRV/r 800/100mg once daily as monotherapy
(monotherapy arm) or in combination with two NRTIs
(triple therapy arm). The investigator-selected nucleoside
analogues were either tenofovir, abacavir or zidovudine in
combination with either lamivudine or emtricitabine.
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Randomization was stratified by HCV antibody status
(anti-HCV negative or positive).
Efficacy and safety assessments
Patients attended study visits at screening, baselines 1 and
2 and then at weeks 4, 24 and thereafter every 24 weeks
until the end of treatment (week 96). Evaluations for
efficacy and safety were carried out at every study visit
according to local standard-of-care; neurocognitive
function was also assessed. Evaluation of plasma HIV-1
RNA levels was determined using the Abbott RealTime
HIV-1 assay (lower quantification limit 40 copies/ml).
Additionally, genotyping was carried out for all patients
with two consecutive HIV-1 RNA levels more than
400 copies/ml. In a subgroup of patients, lumbar
punctures were performed at baseline and again at week
48 to assess HIV-1 RNA levels in the CSF.
Switch of nucleoside analogues in the triple therapy arm
was allowed at any visit in the event of suspected toxicity.
Any subject in the monotherapy arm with virologic
failure could have their treatment intensified with two
nucleoside analogues, provided that major protease
inhibitor mutations had not developed.
The Division of AIDS (DAIDS) grading tables were used
to define clinical and laboratory abnormalities. An
independent Data and Safety Monitoring Board (DSMB)
was established to monitor data on an ongoing basis to
ensure the continuing safety of the patients enrolled into
the study.
Neurocognitive function was assessed using a series of
neuropsychological tests: the revised Hopkins Verbal
Learning Test (HVLT-r), excluding the retention and
recognition tests, the Color Trail Test and the Grooved
Pegboard Test [22–24]. The most common neurocog-
nitive impairments seen in HIV-infected individuals are
those that affect frontal subcortical functions, and as such,
these tests were chosen to detect such changes [25].
Patients participating in the study provided informed
consent prior to any study procedures. Approval from
independent ethics committees and health authorities was
obtained before initiating the study.
Statistical methods
The primary endpoint for the study was confirmed
plasma HIV-1 RNA below 50 copies/ml at week 48
(FDA snapshot algorithm). All patients who discontinued
or switched randomized study medication were con-
sidered nonresponders, inclusive of patients intensifying
treatment with NRTIs in the monotherapy arm. Patients
with missing HIV-1 RNA results at the 48-week visit
were classified as having HIV-1 RNA more than
50 copies/ml.
Assuming a response rate of 90%, 130 patients were
targeted for recruitment in each arm to establish
noninferiority a one-sided significance level of 2.5%,
80% power, a noninferiority margin of 12%, and
allowing for a maximum of 10% of patients to be
excluded from the Per Protocol population. The
primary population was the intention-to-treat (ITT)
population; the Per Protocol population was analyzed to
investigate the impact of exclusion of major protocol
violations.
For the primary analysis, a logistic regression model
including treatment arm and the stratification factor (anti-
HCV positive or negative at screening) was used to
estimate the difference in virologic response rate between
treatment arms, with corresponding 95% confidence
interval (CI). Sensitivity analyses incorporating additional
covariates were conducted to examine the impact of
differences in baseline factors.
In the secondary, switch-included analysis, all patients
who discontinued randomized medications were fol-
lowed up and their HIV-1 RNA levels at week 48 were
included in the analysis, even if they had changed their
antiretroviral treatment.
For the neurocognitive assessment, a total of five scores
were determined and each standardized to give a
normalized z score using the manufacturers’ normative
data [22–24]. An overall score (NPZ-5) was derived by
averaging the scores. TheNPZ-5 score was dichotomized
and considered abnormal if the standardized score was less
than1, indicating below-average performance. Analysis
of covariance (ANCOVA) was used to identify potential
covariates affecting neurocognitive function and to
provide an adjusted estimate for the NPZ-5 score at
week 48 for each treatment group. The difference
between arms was calculated and considered statistically
significant if P< 0.05.
Central nervous system substudy
A subgroup of subjects participated in the CNS substudy.
These subjects underwent a lumbar puncture prior to
baseline and again after 48 weeks of randomized treat-
ment to assess CSF HIV-1 RNA levels. Lumbar puncture
samples were sent to a central laboratory and CSF HIV-1
viral load was determined using the Abbott RealTime
HIV-1 assay.
Patients were considered virologically suppressed in the
CSF if HIV-1 RNA was below 50 copies/ml. In cases
wherein CSF HIV-1 RNA elevations were observed,
other indicators were investigated, including plasma HIV-
1 RNA, other disease markers and presentation of clinical
symptoms. In addition, all CSF samples were assessed for
other key disease markers, including albumin, neopterin
and lymphocyte counts.
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Results
Figure 1 shows the overall patient disposition. In total,
325 patients were screened across 14 countries. Of these,
282 entered the 4-week run-in period and 273 eligible
patients were randomized and treated with DRV/r (137
in the monotherapy arm and 136 in the triple therapy;
ITT population). One further patient was randomized,
but excluded from the ITT population, as the patient did
not take study medication in the treatment phase.
Twenty-seven patients were excluded from the Per-
Protocol population (14 in the monotherapy arm and 13
in the triple therapy arm). The main reasons for exclusion
were low nadir or screening CD4þ cell count, history of
virologic failure, previous mono or dual antiretroviral
therapy or a history of severe depression. There were eight
patients randomized to the study despite having a nadir
CD4þ cell count lower than 100 cells/ml: five in the
monotherapy arm and three in the triple therapy arm.
These patients were protocol violators, and were all
excluded from the per protocol population. Following
the protocol amendment, three of the five patients in the
monotherapy arm with CD4þ nadirs below 100 cells/ml
were intensified with nucleoside analogues despite
having HIV-1 RNA below 50 copies/ml. These three
patients were included in the ITT analyses, but
classified as treatment failures. In addition to the eight
patients with CD4þ nadir below 100 cells/ml, there
were 63 with CD4þ nadir between 100 and 200 cells/ml,
36 in the monotherapy arm and 27 in the triple therapy
arm.
Baseline characteristics by treatment group are shown in
Table 1. Overall, 83% of patients were male, 87% were
white, and the mean age was 42 years. The average
duration of HIV-1 infection was 7.7 years and time since
first antiretroviral therapy was 5.5 years. Twenty-six (10%)
patients were HCV antibody-positive at screening
(13 patients in each arm). However, all 26 patients
had undetectable levels of HCV RNA by PCR. In
the triple therapy arm, concomitant NRTIs were
tenofovirþ emtricitabine for 71% of patients, and
abacavirþ lamivudine for 24% of patients; 6% were taking
other combinations of nucleoside analogues.
Efficacy
In the primary ITT, switch equals failure analysis, 118 of
137 (86.1%) in the DRV/r monotherapy arm compared
with 129 of 136 (94.9%) in the triple therapy arm had
HIV-1 RNA below 50 copies/ml at week 48 using the
FDA snapshot algorithm (Fig. 2a). The difference of
predicted response rates fell below the noninferiority
margin of12% [difference (D);8.7%, 95% confidence
interval (CI), 15.50 to 1.80]. As planned in the
protocol, the primary analysis was repeated adjusting for
differences in baseline disease characteristics; the final
model included treatment group, HCV status, nadir
CD4þ cell count and previous protease inhibitor use. In
this analysis, noninferiority of monotherapy to triple
therapy was shown (D 5.8%; 95% CI, 11.51, 0.14)
according to the predetermined noninferiority margin;
however, the difference remained significantly inferior
statistically. In the per protocol, switch equals failure
analysis, 110 of 123 (89.4%) in the monotherapy arm and
118 of 123 (95.9%) in the triple therapy arm had HIV-1
RNA below 50 copies/ml at week 48 (Fig. 2a).
In the ITT, switch-included analysis, 92.0% of the DRV/r
monotherapy arm and 96.3% of the triple therapy arm
had HIV-1 RNA below 50 copies/ml at week 48; in the
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325 patient screened
282 patient randomized
43 excluded
(failed to meet eligibility criteria)
1 patient never treated
136 patient randomized and treated in 
triple therapy arm (ITT)
123 in per protocol population
137 patient randomized and treated in 
monotherapy arm (ITT)
123 in per protocol population
118/137 patients with HIV RNA < 50
copies/ml at week 48
(primary switch equals failure analysis)
19 patients with protocol defined
treatment failure
129/136 patients with HIV RNA < 50
copies/ml at week 48
(primary switch equals failure analysis)
8 patients with protocol defined
treatment failure
126/137 patients with HIV RNA < 50
copies/ml (switch included analysis)
131/137 patients with HIV RNA < 50
copies/ml (switch included analysis)
8 did not complete 4 week run-in
Fig. 1. Patient flowchart.
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per protocol, switch-included analysis, proportions were
91.9% and 96.7% for the DRV/r monotherapy and triple
therapy arms, respectively (Fig. 2b). In all analyses of the
switch-included population, noninferiority of DRV/r
monotherapy to triple therapy was shown.
In the multiple regression model, low nadir CD4þ cell
counts and previous use of protease inhibitors were the
main predictors of treatment failure (P¼ 0.005 and
P¼ 0.004, respectively). More detailed analysis showed
that a threshold for nadir CD4þ of 200 cells/ml was the
best predictor of treatment failure. In a post-hoc analysis
for patients with nadir CD4þ count below 200 cells/ml,
27 of 41 (65.9%) in the monotherapy arm and 29 of 30
(96.7%) in the triple therapy arm were virologically
suppressed at week 48. For those with a nadir count above
200 cells/ml, the proportion with HIV-1 RNA below
50 copies/ml at week 48 was 91 of 96 (94.8%) in the
DRV/r monotherapy arm and 100 of 106 (94.3%) in the
triple therapy arm (Fig. 2c).
Genotypic data were available for the three patients
who experienced confirmed HIV-1 RNA elevations
400 copies/ml or above (two patients in monotherapy
arm and one patient from triple therapy arm). No
treatment-emergent primary protease inhibitor muta-
tions were detected.
Safety
Summary safety results are shown in Table 2. Overall,
66% of the patients had at least one adverse event up to
week 48; the most common adverse events were
infections or infestations (32%) and gastrointestinal
(16%). Fourteen (5%) patients reported at least one
serious adverse event (nine in the monotherapy arm and
five in the triple therapy arm). Grade 2–4 adverse events
considered treatment-related were more common in the
monotherapy arm (n¼ 12; 9%) than the triple therapy
arm (n¼ 2; 1%). In the monotherapy arm, these were
mainly gastrointestinal adverse events and rises in
cholesterol after discontinuation of tenofovir.
By week 48, five patients (4%) in the monotherapy
arm and one patient (1%) in the triple therapy arm
permanently discontinued darunavir as a result of adverse
events; additionally, one patient in the triple therapy arm
temporarily stopped darunavir treatment. One patient in
the monotherapy arm died of a cardiac arrest and
hyperkalemia deemed unrelated to study treatment by the
trial investigator.
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Table 1. Baseline characteristics by treatment arm (ITT population).
Monotherapy (n¼137) Triple therapy (n¼136) Overall (n¼273)
Mean age (years, SD) 44.6 (11.2) 43.1 (10.4) 43.9 (10.8)
Sex (no. % male) 111 (81) 115 (85) 226 (83)
Race (no. % White) 119 (87) 120 (88) 239 (88)
Mean weight (kg, SD) 76.2 (15.9) 75.9 (13.1) 76.0 (14.5)
Mean BMI (kg/m2, SD) 25.0 (4.6) 24.8 (4.0) 24.9 (4.3)
Known duration of HIV-1 infection (years, SD) 8.1 (5.0) 7.2 (5.0) 7.7 (5.0)
Duration of antiretroviral treatment (years) 5.7 (4.1) 5.3 (4.1) 5.5 (4.1)
HCV antibody positive (no. %) 13 (9) 13 (10) 26 (10)
Baseline HIV-1 RNA category (no. %)
<50 copies/ml 137 (100) 133 (98) 270 (99)
50–<400 copies/ml 0 1 (1) 1 (<1)
400 copies/ml 0 2 (1) 2 (1)
Baseline CD4þ cell count category (no. %)
<200 cells/ml 0 1 (1) 1 (<1)
200–<350cells/ml 14 (10) 8 (6) 22 (8)
350 cells/ml 123 (90) 127 (93) 250 (92)
Nadir CD4þ cell count (no. %)
<100 cells/ml 5 (4) 3 (2) 8 (3)
100–<200cells/ml 36 (26) 27 (20) 63 (23)
200 cells/ml 96 (70) 106 (78) 202 (74)
Clinical stage (CDC) of HIV-1 infection
Category A 96 (70) 110 (81) 206 (75)
Category B 27 (20) 17 (13) 44 (16)
Category C 14 (10) 9 (7) 23 (8)
On first NRTI combination (no. %) 79 (58) 96 (71) 175 (64)
Protease inhibitor naive at screening (no. %) 30 (22) 24 (18) 54 (20)
Protease inhibitor treatment at screening (no. %) 95 (69) 103 (76) 198 (73)
NNRTI treatment at screening (no. %) 35 (26) 31 (23) 66 (24)
Included in CNS substudy (no. %) 37 (27) 34 (25) 71 (26)
Evaluable CSF sample at baseline (no. %a) 28 (76) 29 (85) 57 (80)
Evaluable CSF sample at week 48 (no. %a) 21 (57) 19 (56) 40 (56)
Percentages may not add to 100% because of rounding. CDC, Centers for Disease Control and Prevention; CNS, central nervous system; CSF,
cerebrospinal fluid; HCV, hepatitis C virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor;
RNA, ribonucleic acid; SD, standard deviation.
aShows percentage of subjects included in CNS substudy.
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Overall, 27 (10%) patients experienced neurological
adverse events (13 in the monotherapy arm and 14 in the
triple therapy); the most common neurological adverse
event was headache (n¼ 14; 5%). Nineteen (7%) patients
experienced psychiatric disorders (10 in the monotherapy
arm and nine in the triple therapy), with depression
(n¼ 6; 2%) and insomnia (n¼ 5; 2%), the most common.
One patient in the monotherapy arm was hospitalized
with HIVencephalomyelitis. This patient had a low nadir
CD4þ (17 cells/ml), and at the time of hospitalization
(week 24) had HIV-1 RNA detectable in the plasma
and in the CSF (125 and 2500 copies/ml, respectively);
the patient was re-suppressed and symptoms resolved after
treatment intensification with nucleoside analogues
including high-dose zidovudine (600mg twice daily).
Neurocognitive function
Mean scores increased from screening to week 48 for all
neurocognitive domains in both treatment groups; this is
likely to be the result of a learning effect. There was no
significant difference between the arms in the NPZ-5
score over time (Fig. 3). At week 48, the percentage of
patients with an abnormal neurocognitive score was
12.2% for DRV/r monotherapy and 14.9% for triple
therapy. This difference was not significant.
In ANCOVA analysis, sex, race, and baseline NPZ-5
score were found to have a highly significant effect on the
week 48 NPZ-5 score (P< 0.0001). Alcohol consump-
tion, smoking, history of cardiovascular events and age
were also found to be significantly associated. Results
were not affected by baseline HIV-1 RNA, baseline
CD4þ cell count or nadir CD4þ. After adjustment, mean
1816 AIDS 2015, Vol 29 No 14
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Fig. 2. HIV RNA suppression < 50 copies/ml at week 48.
(a) Primary efficacy analysis: HIV-1 RNA <50 copies/ml
at week 48; FDA snapshot, switch equals failure. Shown
are the percentage of patients suppressed (HIV-1 RNA
<50 copies/ml) in the ITT and per protocol populations,
where switches off randomization treatment were classified
as treatment failure. In both populations, the difference
between the DRV/r monotherapy and DRV/r-based triple
therapy arms did not meet the noninferiority margin of
12% (ITT: D 8.7%, 95%CI 15.50,1.80; per protocol:
D 6.5%, 95% CI 12.94, 0.04). DRV/r, darunavir/ritona-
vir; NRTI, nucleoside reverse transcriptase inhibitor. (b) Sec-
ondary efficacy analysis: HIV-1 RNA <50 copies/ml at week
48; FDA snapshot, switch included. Shown is the percentage
of patients suppressed (HIV-1 RNA <50 copies/ml) in the
ITT and per protocol populations in which switches off
treatment, including re-intensification with NRTIs, were not
considered treatment failures. In both populations, non-
inferiority of DRV/r monotherapy to DRV/r-based triple
therapy was shown (ITT: D 4.3%, 95%CI 9.69, 1.18;
per protocol: D 4.7%, 95% CI 10.49, 1.00). (c) Posthoc
analysis: HIV-1 RNA <50 copies/ml at week 48 by baseline
nadir CD4þ cell count; FDA snapshot, switch equals failure.
Shown are the percentage of patients suppressed (HIV-1 RNA
<50copies/ml) in the ITT switch¼ failure population by
baseline nadir CD4þ cell count. For patients with nadir
CD4þ cell count 200 cells/ml, noninferiority of DRV/r
monotherapy toDRV/r-based triple therapywas shown (Nadir
CD4þ <200: D 30.8%, 95% CI 46.69, 14.94; Nadir
CD4þ 200: D 0.5%, 95% CI 5.80, 6.71).
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NPZ-5 score at week 48 was similar across the two groups
(difference 0.007; 95% CI 0.128, 0.141; P¼ 0.923).
Central nervous system substudy
In total, 71 patients were included in the CNS substudy
(37 monotherapy and 34 triple therapy; 26% of total
participants). The baseline characteristics of this substudy
were similar to those in the overall trial. Of participants in
the substudy, 80% and 56% had evaluable CSF data at
baseline and week 48, respectively (Table 1).
At baseline, all patients with measurable samples were
virologically suppressed in the CSF (HIV-1 RNA
<50 copies/ml). By week 48, one patient had elevated
CSF HIV-1 RNA (654 copies/ml); all other patients
remained suppressed. The patient experiencing CSF
elevations was in the monotherapy arm and was
asymptomatic, however had a concurrent rise in plasma
HIV-1 RNA (77 copies/ml) and a low CD4þ nadir
(166 cells/ml). The patient had neopterin levels above the
reference range at baseline, which further increased to
week 48 (7.13 and 11.15 nmol/l respectively; reference
range 0.00–5.50 nmol/l).
Overall, in the monotherapy arm, mean (standard
deviation) CSF neopterin concentration rose from 4.8
(2.1) nmol/l at baseline, to 6.2 (4.3) nmol/l at week 48. In
the triple therapy arm, mean neopterin level remained
constant over time [4.8 (1.3) at baseline vs. 4.1 (1.2) at
week 48]. Mean CSF albumin was in the normal range
(100–300mg/l) at week 48 for both treatment groups.
Discussion
In the primary 48-week analysis of the PROTEA trial,
using a switch equals failure endpoint, rates of HIV-1
RNA suppression below 50 copies/ml were 118 of 137
(86.1%) in the DRV/r monotherapy arm compared with
129 of 136 (94.9%) in the triple therapy arm. In a
secondary ‘switch-included’ analysis, which classified
HIV-1 RNA suppression after re-introduction of
nucleoside analogues as treatment success, 126 of 137
(92.0%) in the DRV/r monotherapy arm and 131 of 137
(96.3%) in the triple therapy arm showed virological
suppression at week 48.
These results are similar to the final 144-week analysis of
the MONET trial and the 96-week analysis of the
MONOI, which both had a similar design. In the
MONET and MONOI trials, DRV/r monotherapy
displayed lower rates of HIV-1 RNA suppression than
triple therapy in the primary switch equals failure analysis,
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Table 2. Incidence of grade 1–4 adverse events, adverse events leading to permanent discontinuation of darunavir and incidence of nervous
system and psychiatric adverse events by treatment arm.
Monotherapy (n¼137) Triple therapy (n¼136) Overall (n¼273)
Any grade 1–4 all-cause adverse events (no. %)a 96 (70) 83 (61) 179 (66)
Infections and infestations 49 (36) 37 (27) 86 (32)
Gastrointestinal 23 (17) 21 (15) 44 (16)
General/administration site 18 (13) 19 (14) 37 (14)
Musculoskeletal and connective tissue 20 (15) 15 (11) 35 (13)
Skin and subcutaneous tissue 16 (12) 12 (9) 28 (10)
Nervous system 13 (9) 14 (10) 27 (10)
Respiratory, thoracic, and mediastinal 11 (8) 10 (7) 21 (8)
Investigations 13 (9) 6 (4) 19 (7)
Metabolism and nutrition 10 (7) 9 (7) 19 (7)
Psychiatric 10 (7) 9 (7) 19 (7)
Any adverse event leading to permanent stop of DRV (no. %) 5 (4) 1 (1) 6 (2)
Gastrointestinal 3 (2) 0 4 (1)
Metabolism and nutrition 2 (1) 0 2 (1)
Cardiac disorders 1 (1) 0 1 (<1)
Investigations 1 (1) 0 1 (<1)
Nervous system 1 (1) 0 1 (<1)
Pregnancy 0 1 (1) 1 (<1)
Any serious adverse event (no. %) 9 (7) 5 (4) 14 (5)
Any grade 2–4 treatment-related adverse events (no. %) 12 (9) 2 (1) 14 (5)
Grade 1–4 nervous system and psychiatric adverse events (no. %)b
Headache 8 (6) 6 (4) 14 (5)
Depression 3 (2) 3 (2) 6 (2)
Insomnia 3 (2) 2 (1) 5 (2)
Anxiety 2 (1) 1 (1) 3 (1)
Serious nervous system and psychiatric adverse events (no. %)
Encephalomyelitis 1 (<1) 0 1 (<1)
Ischaemic stroke 1 (<1) 0 1 (<1)
Substance abuse 0 1 (<1) 1 (<1)
DRV, darunavir.
aAffecting more than 5% of patients overall.
bAffecting 3 patients overall.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
but similar rates of HIV-1 RNA suppression in the
switch-included analysis [13,15].
In the present study, a low nadir CD4þ count
(<200 cells/ml) was highly predictive of treatment failure
in the monotherapy arm. Patients with a nadir CD4þ cell
count over 200 cells/ml experienced similar response rates
irrespective of randomization arm. There were more
patients with low CD4þ nadir levels in the monotherapy
arm (30%) than the triple therapy arm (22%), which may
have influenced the overall outcome in the primary
efficacy analysis. In studies of monotherapy with LPV/r, a
low nadir CD4þ cell count has been found to be
predictive of treatment failure [26,27]. However, this is
the first trial of DRV/r monotherapy in which nadir
CD4þ cell count was found to be predictive of treatment
response [28,29]. It should be acknowledged, however,
that this was an exploratory subgroup analysis, and the
original exclusion criterion from the PROTEA trial
was a CD4þ nadir below 100 cells/ml; the 200 cells/ml
threshold should be evaluated in future studies of protease
inhibitor monotherapy possibly through stratification
prior to randomization.
Adverse events leading to the discontinuation of therapy
were relatively rare in both arms. Despite this, DRV/r
monotherapy was associated with a slightly higher rate of
treatment-emergent adverse events. The most common
side-effects in both arms were gastrointestinal and
infections and infestations and were generally mild to
moderate in severity. Protease inhibitor use is widely
associated with hepatic and gastrointestinal complications;
however, the increased frequency in the monotherapy arm
is problematic given that a reduction in side-effects is one of
the main reasons for treatment simplification to mono-
therapy [30].
Regarding CNS outcomes, up to week 48, no difference
in neurocognitive function was observed between the
two arms. Furthermore, the incidence of neurological
and psychiatric adverse events was similar. These findings
are generally in agreement with the results from other
randomized protease inhibitor/r monotherapy trials and
cohorts [31–34]. A recent systematic review of 11 studies
in 1267 patients showed no significant difference in risk of
CNS adverse events between PI monotherapy versus
triple therapy [31]. Similarly, in a literature review
assessing neurocognitive performance, protease inhibi-
tor/r monotherapy was not associated with worse
neurocognitive outcomes compared with triple therapy;
however, the authors advised of the need for further
evidence to confirm this finding [32]. Importantly, a low
nadir CD4þ has been shown to be an independent
predictor of neurocognitive impairment [35]. Thus, given
the efficacy findings, it may be especially pertinent that
protease inhibitor monotherapy is avoided in the
subgroup of patients with a low nadir CD4þ cell count.
One patient in the DRV/r monotherapy arm developed
HIV-encephalomyelitis requiring hospitalization; this
patient was found to have substantially elevated HIV-1
RNA in the CSF. Although this could be a casual result
of the switch to protease inhibitor/r monotherapy,
this cannot be confirmed, and could be the result of
disease progression and consequent CNS inflammation.
One further patient in the CNS substudy experienced
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asymptomatic viraemia in the CSF after switching to
monotherapy. This patient had elevated neopterin at
baseline and week 48. In a recent study, a correlation was
observed between high neopterin levels and low-level
HIV-1 RNA replication in the CNS despite plasma
suppression on triple therapy [36]. This suggests that the
CNS could have acted as a viral reservoir in this patient
prior to inclusion in the study. In both cases, subjects
experienced concurrent viraemia in the plasma and both
had a nadir CD4þ cell count below 200 cells/ml.
CSF HIV-1 RNA has been inadequately reported and,
prior to this study, had only been assessed in two
randomized protease inhibitor/r monotherapy trials,
MONOI and MOST [13,27]. In MONOI, CSF
assessments were only taken in symptomatic patients.
Two patients with CNS events in the protease inhibitor/r
monotherapy arm were found to have detectable CSF
HIV-1 RNA despite plasma suppression [13]. In the
MOST study, the proportion with viremia in the CSFwas
significantly higher in patients on monotherapy com-
pared with triple therapy [27]. Despite this, the MOST
study had limited power to detect differences and the
findings have since been contested [37]. In a recent small
cross-sectional study, CSF viral suppression was similar in
patients receiving long-term LPV/r monotherapy com-
pared with LPV/r-containing triple therapy [38]. Of
note, the findings of a recent study suggest low-level CSF
replication can occur in some patients on triple therapy
[36], and thus the effects of the CNSHIV-1 reservoir may
not be restricted to patients receiving protease inhibitor/
r monotherapy.
In summary, DRV/r monotherapy may be suitable as a
tailored treatment option for patients fully suppressed
on therapy, where reintroduction of NRTIs can be
performed as necessary. DRV/r monotherapy may be
most appropriate for patients with nadir CD4þ cell count
greater than 200 cells/mm3; however, this threshold
needs to be further investigated. CNS viral escape remains
a concern and as such, future protease inhibitor
monotherapy trials should be designed to incorporate
CSF HIV-1 RNA evaluations.
Acknowledgements
This study was sponsored by Janssen.
Conflicts of interest
A.A. has received speaker’s honoraria, educational, travel,
and/or research grants from AbbVie, Bristol-Myers
Squibb, Gilead Sciences, Janssen, Merck, and ViiV
Healthcare. J.F. has received speaker’s honoraria, edu-
cational, travel, and research grants and honoraria from
AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen,
Merck, and ViiV Healthcare. M.F. has received speaker’s
honoraria, educational, travel, and research grants from
AbbVie, Bristol-Myers Squibb, Gilead Sciences, and ViiV
healthcare. J.A. has received advisory fees, speaker fees,
and grant support from ViiV healthcare, Tibotec, Janssen,
Abbvie, Bristol-Myers Squibb, Gilead Sciences, MSD,
and Tobira. P.M.G. has received speaker’s honoraria,
educational, travel, and/or research grants from AbbVie,
Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck,
and ViiV Healthcare. The other authors have no conflicts
of interest.
Clinical trial identifier: NCT01448707
Trial registration number: NCT01448707
References
1. Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the use of antiretroviral agents in HIV-1-infected
adults and adolescents. Department of Health and Human
Services. January 29, 2008; 1–128. http://www.aidsinfo.nih.
gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 15
February 2011]
2. Gazzard B, Moecklinghoff C, Hill A. New strategies for low-
ering the costs of antiretroviral treatment and care for people
with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes
Res 2012; 4:193–200.
3. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the
MONET trial using UK antiretroviral drug prices. Appl Health
Econ Health Policy 2011; 9:217–223.
4. Bierman WF, van Aftmael MA, Nijhuis M, Danner SA, Boucher
CA. HIV monotherapy with ritonavir-boosted protease inhibi-
tors: a systematic review. AIDS 2009; 23:279–291.
5. Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson
M, et al. Effectiveness of protease inhibitor monotherapy versus
combination antiretroviral maintenance therapy: a meta-ana-
lysis. PLoS ONE 2011; 6:e22003.
6. Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR.
Protease inhibitor monotherapy and the CNS: peace of mind?
J Antimicrob Chemother 2011; 66:1954–1962.
7. Powderly W, Hill A. Moecklinghoff. Is there a higher risk of
CNS adverse events for PI monotherapy versus triple therapy?
A review of results from randomized clinical trials. HIV Clin
Trials 2014; 15:79–86.
8. Mills A, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I,
Girard P, et al. Once-daily darunavir/ritonavir vs lopinavir-
ritonavir in treatment-naı¨ve, HIV-1 infected patients: 96 week
analysis of ARTEMIS. AIDS 2009; 23:1679–1688.
9. Madruga J, Berger D, McMurchie M, Suter F, Banhegyi D,
Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir
compared with that of lopinavir-ritonavir at 48 weeks in
treatment-experienced, HIV infected patients in TITAN:
a randomized controlled phase III trial. Lancet 2007; 370:
49–58.
10. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy and
safety of darunavir/ritonavir 800/100mg once daily in treat-
ment-naı¨ve and experienced patients. HIV Clin Trials 2008;
9:418–427.
11. Noach, A.B.J., Paulus, G. Safety Assessment Document
TMC114, Tibotec NV, December 2000.
12. Arribas J, Horban A, Gerstoft J, Fattkenheuer G, Nelson M,
ClumeckN, et al. TheMONET trial: darunavir/ritonavir with or
without nucleoside analogues, for patients with HIV RNA
below 50 copies/ml. AIDS 2010; 24:223–230.
13. Katlama C, Valentin MA, Algarte-Genin M, Duvivier C, Lam-
bert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir
maintenance monotherapy in patients with HIV-1 viral sup-
pression: a randomized openlabel noninferiority trial,
MONOI-ANRS 136. AIDS 2010; 24:2365–2374.
Darunavir/ritonavir monotherapy: a randomized trial Antinori et al. 1819
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
14. ClumeckN, Rieger A, Banhegyi D, SchmidtW, Hill A, VanDelft
Y, et al. 96 week results from the MONET trial: a randomized
comparison of darunavir/ritonavir with versus without nucleo-
side analogues, for patients with HIV RNA <50copies/mL at
baseline. J Antimicrob Chemother 2011; 66:1878–1885.
15. Arribas J, Clumeck N, Nelson M, Hill A, van Delft Y, Moeck-
linghoff C. The MONET trial: week 144 analysis of the efficacy
of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r
plus two nucleoside reverse transcriptase inhibitors, for pa-
tients with viral load <50 HIV-1 RNA copies/mL at baseline.
HIV Med 2012; 13:398–405.
16. Valantin MA, Lambert-Niclot S, Flandre P, Morand-Joubert L,
Cabie A, Meynard JL, et al. Long-term efficacy of darunavir/
ritonavir monotherapy in patients with HIV-1 viral suppres-
sion: week 96 results from the MONOI ANRS 136 study.
J Antimicrob Chemoter 2012; 67:691–695.
17. Patron N, Arenas-Pinto A, Dunn D, Stoehr W, Fleck S, Scott K,
et al. The protease inhibitor monotherapy versus ongoing triple-
therapy trial (PIVOT). BHIVA Conference, Liverpool, UK April
2014.
18. European AIDS Clinical Society (EACS) Guidelines. Clinical
management and treatment of HIV infected adults in Europe,
version 7.1 (2014). http://www.eacsociety.org/guidelines/eacs-
guidelines/eacs-guidelines.html [Accessed January 2015]
19. ThompsonM, Aberg J, Cahn P,Montaner J, Rizzardini G, Telenti
A, et al. Antiretroviral Treatment of Adult HIV Infection. 2010
Recommendations of the International AIDS Society–USA
Panel. JAMA 2010; 304:321–333.
20. British HIV Association. British HIV Association guidelines for
the treatment of HIV-1-positive adults with antiretroviral ther-
apy 2012. HIV Med 2014; 15 (Suppl 1):1–85.
21. US Department of Health and Human Services Panel on Anti-
retroviral Guidelines or Adults and Adolescents. Guidelines for
the use of antiretroviral agents in HIV-1-infected adults and
adolescents (2014). http://aidsinfo.nih.gov/guidelines. [Accessed
January 2015]
22. Brandt J, Benedict RHB. Hopkins Verbal Learning test-revised.
Odessa, FL: Psychological Assessment Resources; 2001.
23. D’Elia LF, Satz P, Uchiyama CL, White T. Color Trails Test.
Professional manual. Odessa, FL: Psychological Assessment
Resources; 1996.
24. Lafayette Instrument. Grooved pegboard test user instructions.
Lafayette, IL: Lafayette Instrument Company, Inc.; 2002.
25. Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening
for cognitive impairment in human immunodeficiency virus.
Clin Infect Dis 2011; 53:836–842.
26. Pulido F, Pe´rez-Valero I, Delgardo R, Arranz A, Pasquau J,
Portilla J, et al. Risk factors for loss of virological suppression
in patients receiving lopinavir/ritonavir monotherapy for main-
tenance of HIV suppression. Antivir Ther 2009; 14:195–201.
27. Gutmann C, Cusini A, Gu¨nthard HF, Fux C, Hirschel B,
Decosterd LA, et al. Randomized controlled study demonstrat-
ing failure of LPV/r monotherapy in HIV: the role of compart-
ment and CD4-nadir. AIDS 2010; 24:2347–2354.
28. Arribas J, Pulido F, Hill A, van Delft Y, Moecklinghoff C.
Predictors of long-term HIV RNA suppression on darunavir/
ritonavirmonotherapy in theMONET trial. J Int AIDS Soc 2012;
15 (Suppl 4):18354.
29. Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G,
Duvivier C, Haim-Boukobza S, et al. Factors associated
with virological failure in HIV-1-infected patients receiving
darunavir/ritonavir monotherapy. J Infect Dis 2011; 204:1211–
1216.
30. Wu X, Li Y, Peng K, Zhou H. HIV protease inhibitors in gut
barrier dysfunction and liver injury. Curr Opin Pharmacol
2014; 19:61–66.
31. Powderly W, Hill A, Moecklinghoff C. Is there a higher risk of
CNS adverse events for PI monotherapy versus triple therapy?
A review of results from randomized clinical trials. HIV Clin
Trials 2014; 15:79–86.
32. Pe´rez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR.
Protease inhibitor monotherapy and the CNS: peace of mind?
J Antimicrob Chemother 2011; 66:1954–1962.
33. Pe´rez-Valero I, Gonza´lez-Baeza A, Este´banez M, Monge S,
Montes-Ramı´rezML, Bayo´n C, et al. A prospective cohort study
of neurocognitive function in aviremic HIV-infected patients
treated with 1 or 3 antiretrovirals. Clin Infect Dis 2014; 59:
1627–1634.
34. Winston A, Fa¨tkenheuer G, Arribas J, Hill A, van Delft Y,
Moecklinghoff C. Neuropsychiatric adverse events with rito-
navir-boosted darunavir monotherapy in HIV-infected indivi-
duals: a randomised prospective study. HIV Clin Trials 2010;
11:163–169.
35. Ellis RJ, Badiee J, Florin V, Scott L, Heaton RK, Clifford D, et al.
CD4 nadir is a predictor of HIV neurocognitive impairment in
the era of combination antiretroviral therapy. AIDS 2011;
25:1747–1751.
36. Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW.
Low levels ofHIV-1RNAdetected in thecerebrospinalfluidafter
up to 10 years of suppressive therapy are associated with local
immune activation. AIDS 2014; 28:2251–2258.
37. Paton N, Meynard JL, Pulido F, Arenas-Pinto A, Girard PM,
Arribas J. Inappropriate claim of ‘failure of ritonavir-
boosted lopinavir monotherapy in HIV’ in the Monotherapy
Switzerland/Thailand (MOST) trial. AIDS 2011; 25:393–394.
38. Santos JR, Mun˜oz-Moreno JA, Molto´ J, Prats A, Curran A,
Domingo P, et al. Virological efficacy in cerebrospinal fluid
and neurocognitive status in patients with long-term mono-
therapy based on lopinavir/ritonavir: an exploratory study.
PLoS One 2013; 8:e70201.
1820 AIDS 2015, Vol 29 No 14
